{"id":"W4296529971","doi":"10.1016/s2152-2650(22)01483-5","title":"HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"ABVD; Dacarbazine; Brentuximab vedotin; Medicine; Internal medicine; Vinblastine; Hazard ratio; Oncology; Bleomycin; Progression-free survival; Chemotherapy; Chemotherapy regimen; Confidence interval; Lymphoma; Surgery; Vincristine; Hodgkin lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001477491,0.0004376741,0.001370341,0.0006401464,0.0001513728,0.0008424906,0.00050266,0.0003763628,0.001414177],"category_scores_gemma":[0.001656283,0.0001972672,0.001075376,0.0009320306,0.0002554262,0.0007823898,0.0003630672,0.0006790814,0.0001672754],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006579787,"about_ca_system_score_gemma":0.0005691164,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001095634,"about_ca_topic_score_gemma":0.005037791,"domain_scores_codex":[0.999398,0.0002056275,0.00006598313,0.00008892372,0.0001749784,0.00006644808],"domain_scores_gemma":[0.9990938,0.0003720766,0.0002891646,0.00005843266,0.0001006762,0.00008585572],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0416896,0.00123478,0.3201776,0.002611438,0.01366951,0.0003745153,0.0001591201,0.002175094,0.006207317,0.000245281,0.008663159,0.6027926],"study_design_scores_gemma":[0.008474893,0.0116592,0.9421121,0.0005198853,0.01487375,0.001656511,0.0001648492,0.002108949,0.001821509,0.0004501892,0.01608116,0.00007702607],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8961838,0.09629828,0.0004345984,0.0009959228,0.0001724151,0.0001294666,0.002039082,0.00008484766,0.003661641],"genre_scores_gemma":[0.9740683,0.02004028,0.0006189774,0.001016858,0.0001913571,0.00005421526,0.003193884,0.00001485715,0.0008012783],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001477491,"threshold_uncertainty_score":0.007813811,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02059907530529329,"score_gpt":0.2973169802176248,"score_spread":0.2767179049123314,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}